Semaglutide vs. Tirzepatide in 2026: Same Two Molecules, Nine Different Pharmacies

For years the semaglutide-versus-tirzepatide debate ran on cross-trial guesswork. SURMOUNT-5 wrapped in 2025 and finally handed the field a number people could argue about instead of estimate. Over 72 weeks, tirzepatide took patients to roughly −20.2% of baseline body weight. Semaglutide, in the same room, landed at −13.7%. It was the first direct head-to-head of the two molecules that matter most for obesity treatment right now, and it settled the "which one loses more weight, on average" question with far fewer asterisks than the usual math.

Where you live decides what those two molecules are even called. In Chicago the comparison reads Wegovy vs. Zepbound. In Seoul it's 위고비 and 마운자로. In Tokyo, ウゴービ and ゼップバウンド both carry obesity labels, while マンジャロ stays diabetes-only. In Shanghai, both obesity brands — 诺和盈 and 穆峰达 — are already on shelves. Two molecules, nine markets, nine separate pricing and coverage stories.

US access gets the most ink below, simply because it's the frame most readers arrive with. But the rest of the world is here too, for anyone traveling, counseling patients across borders, or just trying to make sense of a friend's prescription overseas. The pen in your fridge in Chicago is the same molecule that costs about a third as much in Madrid. That part isn't a rumor.

Two molecules doing two different jobs at the receptor

Semaglutide is a single-receptor agonist. It mimics GLP-1, a gut hormone your body releases after a meal, and it binds only the GLP-1 receptor. That slows gastric emptying, quiets appetite signaling in the hypothalamus, and sharpens glucose-dependent insulin secretion. One lever, pulled hard.

Tirzepatide pulls two levers at once. It's a dual agonist of the GIP receptor and the GLP-1 receptor. GIP is the other big incretin hormone, and on its own it's a fairly weak weight-loss lever. Pair it with GLP-1 agonism, though, and the combination seems to do more than either pathway manages alone — better insulin sensitivity, measurably different lipid handling, and what looks like amplified satiety signaling. Researchers are still working out the exact mechanism in animal and early human models. The clinical output, on the other hand, is anything but subtle.

That mechanistic gap is why the numbers diverged long before SURMOUNT-5 ever put the two in the same trial. STEP 1, published in NEJM in 2021, put semaglutide 2.4 mg weekly at −14.9% over 68 weeks in adults with obesity and no diabetes. SURMOUNT-1, a year later, put tirzepatide 15 mg weekly at −20.9% over 72 weeks in a similar population. Call it 7 to 8 percentage points — across separate trials, with slightly different durations.

And that gap-across-trials is the catch. The populations aren't identical, endpoints drift, placebo arms behave differently. Which is the whole reason SURMOUNT-5 carried weight: it stopped comparing apples to oranges and put both drugs in the same room.

What SURMOUNT-5 actually showed

The design was clean: 751 adults with obesity and no diabetes, 72 weeks, maximum tolerated doses of either tirzepatide (10 or 15 mg weekly) or semaglutide 2.4 mg weekly. The result: −20.2% vs −13.7%. In relative terms, roughly 47% more weight lost on tirzepatide. Sit with that one number and most of the GLP-1 internet snaps into focus.

What does it mean on the scale? A patient starting at 200 lb loses about 27 lb on semaglutide and about 40 lb on tirzepatide. Starting at 90 kg, that's about 12 kg vs about 18 kg. If your clinical target is 10 to 12% off baseline — the range that tends to move blood pressure, fasting glucose, and sleep quality — either drug clears the bar comfortably. If you're chasing past 20%, tirzepatide got there for most SURMOUNT-5 participants, and semaglutide got there for a smaller share.

The head-to-head closed the debate on the average, not on the individual. Response is still a distribution, not a single line.

Here's a second number worth keeping in your pocket. SELECT, the cardiovascular outcomes trial for semaglutide 2.4 mg, ran about 40 months and reported a 20% reduction in major adverse cardiovascular events in people with established cardiovascular disease and obesity or overweight. That readout is what earned Wegovy a cardiovascular indication in both the US and EU. Tirzepatide has no comparable outcomes data yet — SURPASS-CVOT is still running, and its primary endpoint is a way off. So you end up holding two true things at once: tirzepatide leads on average weight loss, semaglutide leads on documented heart benefit.

Nine markets, same two molecules, nine different shelves

The brand name changes the second you cross a border, even when the molecule in the pen doesn't. Here's the regulator-level snapshot as of April 2026:

The US and Japan split the tirzepatide brand. In both, Zepbound (ゼップバウンド in Japan) is the obesity label and Mounjaro is the type 2 diabetes label. Everywhere else on this list, tirzepatide ships under a single brand — Mounjaro, or its localized equivalent — for both conditions. A Korean patient on 마운자로 doesn't pick up a second brand for obesity; the one pen covers both approved uses. So if you're a US reader filling a prescription in Korea or Europe, don't blink when "Mounjaro" shows up on an obesity script. That's normal across most of this list.

Japan splits the tirzepatide brand the way the US does. マンジャロ has been approved for type 2 diabetes since 2022 and launched in April 2023, and it stays T2D-only. The obesity indication ships under a separate brand, ゼップバウンド (Zepbound), which cleared PMDA in December 2024. For Japanese patients looking specifically at obesity treatment, ウゴービ and ゼップバウンド are both labeled GLP-1 options, squarely in 自費 (self-pay) territory — ウゴービ runs roughly 70,000–84,000 JPY per month.

Korea's tirzepatide obesity approval landed in late 2024, and supply is still catching up. 위고비 launched in October 2024 and hit queue problems almost on day one; 마운자로 for obesity was approved back in July 2024, with first pharmacy stock trickling in through 2025. Cash pricing runs 21–37만원 a month for 위고비 depending on dose, and roughly 17–27만원 for 마운자로.

China already has both obesity brands on shelves. 诺和盈 — Novo's obesity brand name for semaglutide in mainland China — launched in November 2024. 穆峰达, Lilly's tirzepatide brand, picked up the obesity indication and launched in 2025. Both are self-pay through private pharmacies and a handful of urban telehealth clinics.

Ozempic is not Wegovy. This is the single most common mix-up in consumer conversations, in every market on this list. The type 2 diabetes semaglutide brand almost always carries a different name and a lower dose ceiling than the obesity semaglutide brand: Ozempic vs Wegovy in the US, 오젬픽 vs 위고비 in Korea, オゼンピック vs ウゴービ in Japan, 诺和泰 vs 诺和盈 in mainland China. Same molecule, different label, different pen, different cost. Get precise about it before you compare notes with a friend overseas — you may not be talking about the same thing.

Dose ladders: five steps vs six steps

Both drugs titrate. Nobody starts at the therapeutic dose. That isn't a marketing decision — it's a tolerance one. GI side effects scale with the dose, and a slow climb is how most people get through the first two months without quitting.

Semaglutide has five rungs; tirzepatide has six. The usual climb to top dose runs roughly 16–20 weeks for semaglutide and 20–24 weeks for tirzepatide, assuming no pauses for GI trouble. Most people do pause or step back at least once, so the real-world time-to-max tends to stretch past those windows.

US readers have one fresh wrinkle: oral Wegovy at 25 mg daily was approved by the FDA in January 2026 and is starting to land on formularies. The oral version is a single-step 25 mg dose, no ladder, and it replaces the pen outright for patients who can't or won't inject. Tirzepatide has no oral counterpart. Dual agonists are tougher to deliver in a pill — bigger molecule, more moving parts — and Lilly's oral bet is orforglipron (Foundayo), a separate GLP-1 mono-agonist, not a swallowable tirzepatide.

Side effects: close profiles, not identical

GI symptoms run the show on both drugs. They peak during titration, ease off somewhere between weeks 8 and 12, and stand as the #1 reason people quit.

Tirzepatide reads a touch gentler on GI symptoms at the top dose, and the SURMOUNT-5 head-to-head broadly agreed — nausea ran a few percentage points lower on the tirzepatide arms. In practice, that gap is smaller than the variation between any two people. Plenty sail through semaglutide and feel wrecked on tirzepatide. Plenty land the other way around. The tolerability profile is a trend, not your destiny.

The rarer serious signals apply to both molecules in roughly the same way:

• Acute pancreatitis — infrequent but real. Sharp, persistent abdominal pain that radiates to the back deserves same-day medical attention, not a wait-and-see.
• Gallbladder disease — rapid weight loss of any kind raises gallstone risk; GLP-1 drugs appear to nudge the baseline risk upward.
• Diabetic retinopathy worsening — documented for semaglutide in patients with type 2 diabetes and pre-existing retinopathy. Worth naming at your visit if you have diabetic eye disease.
• Hypoglycemia — not from GLP-1 drugs alone, but in combination with insulin or a sulfonylurea, the risk climbs fast. Dose adjustments of the other drugs are standard practice.
• Thyroid C-cell tumor warning — both drugs carry a boxed warning based on rodent data. Personal or family history of medullary thyroid carcinoma or MEN2 is a hard contraindication for both.

"Month three was the turning point. The sulfur burps got better, the nausea got quieter, and the scale started moving for real." — a common rhythm people describe on r/GLP1 and r/Zepbound. Trust the arc, not any single week.

Safety context that belongs up front, not in the fine print

A few things worth having ready before the visit, instead of skimming a pamphlet on the way out the door.

Pregnancy. Neither drug is approved in pregnancy. Both Novo Nordisk and Lilly recommend stopping at least two months ahead of a planned conception, given the long half-life of these molecules (roughly a week) and the theoretical risks to fetal development. If you're of reproductive age and not planning a pregnancy, reliable contraception belongs in the plan from the start — not bolted on later.

Medication interactions. GLP-1 drugs slow gastric emptying, which can shift how oral medications with narrow therapeutic windows get absorbed. Warfarin, thyroid hormone, some seizure medications — bring the full list of what you take, supplements included, even the ones you'd rather not admit to.

For patients with type 2 diabetes, the insulin and sulfonylurea interaction is the one that matters most. Layering a GLP-1 on top of either often calls for cutting the dose of the older agent, and that's a call the endocrinologist should make, not you.

People sometimes figure stopping cold is harmless because there's no physical dependence. True enough — no withdrawal in the classical sense. But STEP 4 data showed that going off semaglutide brought back about two-thirds of the lost weight inside a year. That's not a side effect of quitting. That's obesity doing what chronic conditions do. Choosing to stop is entirely legitimate. Assuming the weight stays gone without treatment usually isn't.

The compounded question (mostly a US thing now)

From late 2022 through early 2024, shortages of both semaglutide and tirzepatide pushed tens of thousands of US patients toward compounded GLP-1s — drugs made by 503A or 503B pharmacies, not FDA-approved, but legal as long as the branded products sat on the FDA shortage list.

By April 2026, both branded products are off that list. Tirzepatide came off in late 2024; semaglutide followed in early 2025. With the shortage resolved, compounded versions of either molecule are no longer broadly permitted. The FDA has been sending warning letters, and the larger telehealth compounders have mostly moved to branded cash-pay pricing through LillyDirect and NovoCare.

This reaches non-US readers too, just sideways. Any social-media ad dangling compounded tirzepatide at a suspiciously low price in 2026 is almost certainly unlicensed or unsafe, no matter which country's feed it shows up in. The shortage loophole that justified compounded GLP-1s at scale has closed.

US pricing in April 2026, and what the other eight markets look like

US commercial list prices are the steepest on the planet, which is exactly why the cash-pay programs have become the number most people actually quote.

• Wegovy — list around $1,349 per month. NovoCare cash-pay around $499 per month for eligible patients without insurance coverage.
• Oral Wegovy 25 mg — around $499 per month cash.
• Zepbound — list around $1,086 per month. LillyDirect cash-pay around $349 at the 2.5 mg starter dose, stepping up toward $499 at higher doses.

For context against the rest of the list:

• Korea — 위고비 21–37만원/mo; 마운자로 17–27만원/mo. Both 비급여.
• Japan — ウゴービ self-pay about 70,000–84,000 JPY/mo. マンジャロ for T2D only, 7,000–15,000 JPY/mo at 3-wari insurance.
• China — 诺和盈 about 1,300–1,800 元/mo. 穆峰达 about 1,500–2,000 元/mo.
• Taiwan — Wegovy about NT$8,000–12,000/mo. 猛健樂 about NT$7,500–11,000/mo.
• Hong Kong — Wegovy about HK$3,500–5,000/mo. Mounjaro similar.
• Spain — Wegovy private pharmacy about 380–410 €/mes. Public reimbursement limited.
• France — Wegovy private pay about 300–400 €/mo. Mounjaro obésité has conditional reimbursement since late 2024 for select patients.
• Saudi Arabia — Wegovy about 1,200–1,800 SAR/mo. Mounjaro about 1,500 SAR/mo.
• UAE — Wegovy about 1,800–2,400 AED/mo. Mounjaro about 2,000 AED/mo.

Every figure here is an April 2026 snapshot, and they move — manufacturer programs change, local supply tightens and loosens, and the numbers drift with them.

Private-pay almost everywhere outside the US, even in markets with strong public healthcare. Obesity treatment is still largely out-of-pocket around the world, and that's the most honest line to open a family budget conversation with.

Questions worth bringing to your next visit

Screenshot these. Most people walk in with two vague questions and walk out with three new ones and no answers.

1. Given my weight, my comorbidities, and my family history, which molecule would you start me on, and why that one?
2. If I tolerate the starter dose well, how fast do you typically escalate?
3. What is my target? A percentage of baseline, a number on the scale, or a clinical marker like HbA1c or blood pressure?
4. If nausea or constipation becomes disruptive in the first six weeks, what is your protocol — hold the dose, step back, add a supportive medication, or ride it out?
5. If my plan denies the prior authorization, what language do you usually use in the appeal?
6. What muscle-loss and protein-intake guidance do you give patients on these drugs?
7. When and how do you think about stopping, and what is your maintenance approach after goal weight?
8. Is there anything in my history — thyroid nodules, gallbladder, pancreatitis, retinopathy, pregnancy plans — that would change the answer to question 1?

Those eight cover most of what tends to go sideways in the first six months. And clinicians far prefer a specific question to a wide-open "so what do you think?"

Where your market sits in April 2026

A locale-by-locale read. Skip to the one that matches you.

If you're in the US, both molecules are on shelves, you've got the cleanest cash-pay programs in the world, a Medicare loophole tied to Wegovy's cardiovascular indication, and messy commercial-insurance coverage that lives or dies by your employer's formulary. The oral Wegovy 25 mg launch in January 2026 is the newest variable, and it'll matter most for patients who can't do injections.

If you're in Korea, both molecules are available and 비급여. Supply for 위고비 was rough through late 2024 and has since steadied; 마운자로 for obesity launched in 2025, and a few dose strengths are still harder to track down at specific pharmacies.

If you're in Japan, both molecules now have an obesity label: ウゴービ for semaglutide and ゼップバウンド (Zepbound) for tirzepatide, the latter cleared by PMDA in December 2024. Both sit in 自費 territory, and マンジャロ stays T2D-only.

If you're in mainland China, both obesity brands — 诺和盈 and 穆峰达 — are available via private pharmacy or urban telehealth, all self-pay. Steer clear of grey-market channels given the enforcement environment.

If you're in Taiwan or Hong Kong, you get the full brand set at private-pay pricing that sits closer to European levels than US ones.

If you're in the EU, local reimbursement decides whether your out-of-pocket resembles France's partial public coverage or Spain's mostly private pay. Both the Wegovy and Mounjaro obesity extensions are fully approved — it's the payer side that swings.

If you're in Saudi Arabia or the UAE, both are available and almost entirely private. Some UAE private insurance plans will cover with prior authorization from an endocrinologist; public coverage for obesity stays rare.

The molecules don't change when you cross a border. The shelf does, every single time. If this sounds like treatment worth starting, the real decision gets made in a focused 20-minute appointment — with someone who has prescribed both drugs and actually knows your local coverage rules. Not on Reddit. Not in a TikTok comment thread. Not off an FDA press release. In the room, with the person who can write the script.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. All GLP-1 medications discussed are prescription drugs — do not start, stop, or change any medication without consulting your doctor. Individual results vary. For the most current prescribing information, refer to the FDA-approved labeling for each drug.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app